Kim Ji-Hae, Lee Kun-Joo, Lee Seung-Woo
Department of Life Sciences, Pohang University of Science and Technology (POSTECH), Pohang 37673, Korea.
Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology (POSTECH), Pohang 37673, Korea.
BMB Rep. 2021 Jan;54(1):21-30. doi: 10.5483/BMBRep.2021.54.1.257.
Clinical trials have demonstrated that an increased number of effector cells, especially tumor-specific T cells, is positively linked with patients' prognosis. Although the discovery of checkpoint inhibitors (CPIs) has led to encouraging progress in cancer immunotherapy, the lack of either T cells or targets for CPIs is a limitation for patients with poor prognosis. Since interleukin (IL)-2 and IL-7 are cytokines that target many aspects of T-cell responses, they have been used to treat cancers. In this review, we focus on the basic biology of how these cytokines regulate T-cell response and on the clinical trials using the cytokines against cancer. Further, we introduce several recent studies that aim to improve cytokines' biological activities and find the strategy for combination with other therapeutics. [BMB Reports 2021; 54(1): 21-30].
临床试验表明，效应细胞数量的增加，尤其是肿瘤特异性T细胞，与患者的预后呈正相关。尽管检查点抑制剂（CPI）的发现已在癌症免疫治疗中取得了令人鼓舞的进展，但缺乏T细胞或CPI的靶点是预后不良患者的一个限制因素。由于白细胞介素（IL）-2和IL-7是针对T细胞反应多个方面的细胞因子，它们已被用于治疗癌症。在这篇综述中，我们关注这些细胞因子如何调节T细胞反应的基本生物学特性，以及使用这些细胞因子治疗癌症的临床试验。此外，我们介绍了几项旨在改善细胞因子生物学活性并寻找与其他疗法联合策略的最新研究。[《BMB报告》2021年；54(1): 21-30]
